India’s ‘Cautious’ View Dulls Sanofi Hopes For Early Dengvaxia Launch
Executive Summary
An early rollout of Sanofi Pasteur’s dengue vaccine in India is looking less likely with a senior functionary of the health ministry telling Scrip why India needs to take a “cautious view” on the product’s licensure in the country, at least for now. Sanofi, though, has sought the “best regulatory solution” that can facilitate access to the product.
You may also be interested in...
Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?
WHO’s recommendation around a pre-vaccination screening strategy for Sanofi’s Dengvaxia could potentially dull the prospects of the product further, especially in emerging markets with stretched healthcare resources. One industry expert suggests that governments should probably consider introducing the vaccine only after “better tests and tools” become available.
First Zika Cases Reported In India; Government Says No Need For Panic
WHO reports confirmation of three cases of Zika infection in the western state of Gujarat but a top Indian government official assures there’s no need for “panic” as there have been no fresh reports of the virus in months. Hyderabad-based Bharat’s Zika vaccine cleared to begin Phase I trials.
Come Flood Or High Water – How BioNet Is Shaping Its Vaccine Ambitions
Emerging Company Profile: Thailand-based BioNet stuck it out despite widespread flooding at its site and now expects to take its pertussis vaccine to key Western markets.